期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 179, 期 -, 页码 133-146出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.06.042
关键词
BRAF(V600E); Photopharmacology; Photocontrolled inhibitor; Metastatic melanoma; Azobenzene
资金
- Netherlands Organization for Scientific Research (NWO-CW VIDI grants) [723.014.001, 723.012.005]
- DFG [SFB 677]
Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAF(V600E) mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results - paradoxically - in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAF(V600E )kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAF(V600E) inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues. (C) 2019 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据